These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
    Author: Iannetta M, Cesta N, Stingone C, Malagnino V, Teti E, Vitale P, De Simone G, Rossi B, Ansaldo L, Compagno M, Spalliera I, Di Lorenzo A, Landi D, Nicoletti CG, Marfia GA, Andreoni M, Sarmati L.
    Journal: Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745.
    Abstract:
    BACKGROUND: Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS). OBJECTIVES: to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment. METHODS: Case series. RESULTS: Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae. CONCLUSION: Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection.
    [Abstract] [Full Text] [Related] [New Search]